Get started
Work

128P Real-world survival outcomes in MSS colorectal cancer(CRC) patients based on mesothelin(MSLN) expression

Year: 2024
Type: article
DOI: 10.1016/j.annonc.2024.05.138
Authors: M. Malla, S.K. Deshmukh, S. Wu, T. Samec, M. Akce, D. Olevian, R. Elnaili, J. Xiu, A. Farrell, H.J. Lenz, E. Lou, S. Goel, D. Spetzler, R.M. Goldberg, L. Hazlehurst, B.F. El-Rayes
Institutions: University of Alabama at Birmingham, Caris Life Sciences (United States), West Virginia University, University of Southern California, USC Norris Comprehensive Cancer Center, University of Minnesota, Masonic Cancer Center, Rutgers Cancer Institute
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: bronze
Funders: Amgen, Bristol-Myers Squibb, Pfizer, AstraZeneca, Sanofi, American Society of Clinical Oncology, Celgene, F. Hoffmann-La Roche, Array BioPharma, Taiho Pharmaceutical, BeiGene, Cancer Research UK, Fundación Científica Asociación Española Contra el Cáncer, European Society for Medical Oncology, Humanitas University, Servier, Novartis Farmacéutica, Deutschen Konsortium für Translationale Krebsforschung, PharmaMar, Menarini Group, INCLIVA Instituto de Investigación Sanitaria, Humanitas Research Hospital, Oncode Institute, Genentech, HORIZON EUROPE Framework Programme, Daiichi Sankyo Europe, Cilag
OpenAlex ID: W4400143187
FWCI:
Cites:
Cited by:
Related to: 10